Press release Communiqué de presse
Press release Communiqué de presse
April 21, 2021 21 April, 2021
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
April 21, 2021 9:00 AM ET
LONDON, ONTARIO – April 21, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that it will host a virtual Key Opinion Leader (KOL) event on thyroid disease, current treatment options and the potential of a novel cell therapy treatment approach for postoperative hypothyroidism. The event will take place on Tuesday April 27th, 2021, at 1:00 PM ET.
The event will feature a presentation from Dr. Sam Wiseman, a leading academic thyroid/parathyroid surgeon and internationally recognized expert in the management of thyroid and parathyroid disease.
"This KOL event will provide the unique opportunity for our investors to learn about thyroid disease, current treatments, and exciting advancements towards a novel cell therapy treatment approach aimed to provide a functional cure for patients suffering from postoperative hypothyroidism," said Dr. Philip Toleikis, President and CEO of Sernova. "Participants will also be able to enter into a conversation through a Q&A period with Dr. Wiseman, a prominent physician in the management of thyroid disease."
Dr. Wiseman's presentation will be made available on Sernova's website before the call. All questions to Dr. Wiseman, can be submitted to firstname.lastname@example.org prior to the call.
To register and access the Zoom link for this event, please click:
Following the event, a recording will be available at www.sernova.com.
ABOUT SERNOVA'S HYPOTHYROID PROGRAM
Sernova's immediate approach in treating hypothyroid disease is to transplant healthy thyroid tissue following thyroidectomy (removal of the thyroid gland) into the pre-implanted vascularized Cell Pouch to recover the normal function of the thyroid gland. In collaboration with Dr. Wiseman, preclinical proof of concept work conducted under a grant from the British Columbia Transplant Foundation is contributing to advancing Sernova's plans to conduct clinical assessment of the Cell Pouch with transplanted thyroid tissue in patients suffering from hypothyroid disease. Sernova's treatment goal is to preserve thyroid function and improve patient quality of life relative to current treatments.
Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non- cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000 thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation are diagnosed with benign diseases after their procedure. Patients with Grave's disease and thyroid nodules undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid hormone replacement.
Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, patients often suffer from deleterious side-effects including weight gain, depression, headaches, and cardiovascular disease, with resultant negative impact on quality of life, and significant costs to the healthcare system. We believe Sernova's development of new therapeutic strategies to overcome hypothyroidism has the potential to meet an important unmet medical need.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Tel: (519) 858-5126
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.